There is no FDA-approved blood test for Parkinson’s disease, and diagnosis still relies primarily on a neurologist’s clinical evaluation. However, several blood-based tests are in development or available on a limited basis, and one spinal fluid test is already commercially available. The landscape is shifting quickly, with some experimental blood tests showing over 90% accuracy in research settings.
How Parkinson’s Is Currently Diagnosed
Parkinson’s disease is diagnosed through a clinical exam, not a lab test. Neurologists follow criteria established by the Movement Disorder Society, which require the presence of specific motor symptoms: slowed movement (bradykinesia) combined with either a resting tremor or muscle rigidity. From there, the doctor looks for supporting evidence and rules out other conditions that can mimic Parkinson’s, like certain medications or other neurological diseases.
This process works reasonably well in experienced hands, but it has real limitations. Diagnosis depends heavily on the skill of the individual clinician, and early-stage Parkinson’s can look a lot like other movement disorders. Studies have found that even specialists misdiagnose Parkinson’s in roughly 10 to 20 percent of cases, particularly early on. That’s a big part of why researchers have been pushing hard to develop an objective lab test.
The Alpha-Synuclein Seed Amplification Assay
The most promising diagnostic test available right now detects misfolded alpha-synuclein, the protein that clumps in the brains of people with Parkinson’s. The test, called a seed amplification assay (SAA), works by amplifying tiny amounts of the abnormal protein until it’s detectable. In late 2024, the FDA issued a Letter of Support encouraging drug developers to use this assay in clinical trials, a signal that the agency considers it a credible biomarker even though it hasn’t granted full diagnostic approval yet.
Most of the validated SAA testing so far uses spinal fluid, not blood. But researchers have been adapting the technology for blood samples with encouraging results. One 2023 study using a blood-based version reported 94.6% sensitivity and 92.2% specificity, meaning it correctly identified the vast majority of people with Parkinson’s and rarely flagged healthy people as positive. A 2024 study found somewhat lower but still strong numbers: about 80% sensitivity and 90% specificity.
A commercial spinal fluid version called SAAmplify (previously the SYNTap test) has been available since 2021 through Amprion. It costs $1,500 out of pocket because insurance doesn’t cover it. The company is working toward full FDA approval. A separate test called Syn-One detects the same abnormal protein through a small skin biopsy rather than blood or spinal fluid, and it can be billed through Medicare, with some private insurance contracts in place.
A Blood Test Based on Mitochondrial DNA Damage
Researchers at Duke University, funded by the NIH, developed a different kind of blood test that detects damage to DNA inside mitochondria, the energy-producing structures in your cells. The test, called Mito DNADX, uses the same PCR technology behind COVID tests to pick up mitochondrial DNA damage that conventional methods miss.
In initial studies, the test found elevated mitochondrial DNA damage in blood samples from people with Parkinson’s compared to people without it. It worked in people who carried a known genetic mutation linked to Parkinson’s and in those with no identifiable genetic risk factors. Results stayed consistent over time and weren’t affected by whether someone was taking Parkinson’s medications. The researchers were able to calculate a cutoff value that reliably separated people with Parkinson’s from healthy volunteers.
This test has an additional potential use. The mitochondrial damage it detects appears to be driven by abnormal activity of a specific protein that drug companies are already targeting with new therapies. That means the test could eventually serve double duty: helping diagnose Parkinson’s and tracking whether a treatment is working in real time. It is not yet commercially available.
What These Tests Can and Can’t Do
Even the most accurate experimental blood tests aren’t yet replacements for a clinical diagnosis. A 90% sensitivity rate sounds impressive, but it means roughly 1 in 10 people with Parkinson’s would get a negative result. And no single biomarker captures the full picture of a disease as complex as Parkinson’s, which likely involves multiple overlapping biological processes.
Where these tests may prove most valuable first is in distinguishing Parkinson’s from conditions that look similar. One study found that a blood marker called neurofilament light chain could differentiate between Parkinson’s and multiple system atrophy, a rarer condition that mimics Parkinson’s early on, with an accuracy score of 0.93 out of 1.0. That kind of precision in separating lookalike diseases could prevent years of misdiagnosis for some patients.
The tests also hold promise for catching Parkinson’s earlier, potentially years before motor symptoms appear. People in the earliest stages, or those with risk factors like a specific sleep disorder called REM sleep behavior disorder, could benefit from early detection once disease-modifying treatments become available.
What’s Available to You Right Now
If you’re wondering whether you can walk into a clinic and get a blood draw to test for Parkinson’s today, the short answer is no. The blood-based versions of these tests remain in research phases. What is available commercially are the spinal fluid SAA test ($1,500, self-pay) and the Syn-One skin biopsy, which has some insurance coverage. Both require a doctor’s order.
These tests are typically used as supplementary tools when a diagnosis is uncertain, not as first-line screening. If you or someone you know has symptoms that might suggest Parkinson’s, a neurologist specializing in movement disorders remains the most reliable starting point. The clinical exam, while imperfect, is still the standard, and the new tests are being developed to support that process rather than replace it entirely.